{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:42:12Z","timestamp":1788252132881,"version":"build-2803163510"},"reference-count":27,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>International Working Group (IWG) and European LeukemiaNet (ELN) response definitions are utilized to evaluate the efficacy of new agents for childhood acute myeloid leukemia (AML) for regulatory purposes. However, these criteria are not consistent with definitions used in pediatric AML trials or with standard pediatric practice to proceed with subsequent therapy cycles prior to IWG\/ELN-defined count recovery. We retrospectively analyzed data from the two most recent Phase 3 pediatric AML clinical trials conducted by the Children\u2019s Oncology Group (COG) to assess the incidence, timing, and prognostic significance of count recovery following induction chemotherapy. Of the patients with fewer than 5% bone marrow blasts at the end of first induction, 21.5% of patients proceeded to a second induction cycle prior to achieving ANC \u2265 500 cells\/\u03bcL and platelets \u2265 50,000 cells\/\u03bcL, both well below the IWG\/ELN thresholds of ANC &gt; 1000 cells\/\u03bcL and platelets &gt; 100,000 cells\/\u03bcL. In these two sequential childhood AML Phase 3 trials, neither ANC nor platelet recovery predicted survival. Intensification of treatment through the initiation of subsequent therapy cycles prior to attainment of IWG\/ELN-defined CR is common practice in clinical trials for children with AML, suggesting that updated response definitions are needed for pediatric AML.<\/jats:p>","DOI":"10.3390\/cancers14030616","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T11:02:53Z","timestamp":1643194973000},"page":"616","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8760-5202","authenticated-orcid":false,"given":"Lauren","family":"Pommert","sequence":"first","affiliation":[{"name":"Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH 45229, USA"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Cancer and Blood Disorders Center, Seattle Children\u2019s Hospital, Seattle, WA 98105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Gerbing","sequence":"additional","affiliation":[{"name":"Children\u2019s Oncology Group, Monrovia, CA 91016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Brodersen","sequence":"additional","affiliation":[{"name":"Hematologics Inc., Seattle, WA 98121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Loken","sequence":"additional","affiliation":[{"name":"Hematologics Inc., Seattle, WA 98121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Gamis","sequence":"additional","affiliation":[{"name":"Children\u2019s Mercy Hospital and Clinics, Kansas City, MO 64108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Aplenc","sequence":"additional","affiliation":[{"name":"Division of Oncology, The Children\u2019s Hospital of Philadelphia, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Alonzo","sequence":"additional","affiliation":[{"name":"Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA 90032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Anders","family":"Kolb","sequence":"additional","affiliation":[{"name":"Nemours Center for Cancer and Blood Disorders\/Nemours Children\u2019s Health, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/pbc.24464","article-title":"Epidemiology of childhood acute myeloid leukemia","volume":"60","author":"Puumala","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"26417","DOI":"10.18632\/oncotarget.25443","article-title":"Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling","volume":"9","author":"Tarlock","year":"2018","journal-title":"Oncotarget"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.1990.8.5.813","article-title":"Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia","volume":"8","author":"Cheson","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Estey","year":"2010","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.2009.25.1066","article-title":"Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study","volume":"28","author":"Walter","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase III Children\u2019s Oncology Group trial AAML","volume":"32","author":"Gamis","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: A report from the Children\u2019s Oncology Group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1182\/bloodadvances.2020002070","article-title":"Morphologic remission status is limited compared to DeltaN flow cytometry: A Children\u2019s Oncology Group AAML0531 report","volume":"4","author":"Brodersen","year":"2020","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric Estimation from Incomplete Observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_13","unstructured":"Kalbfleisch, J., and Prentice, R. (1980). The Statistical Analysis of Failure Time Data, John Wiley."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Cox, D.R. (1992). Regression Models and Life-Tables. Breakthr. Stat., 527\u2013541.","DOI":"10.1007\/978-1-4612-4380-9_37"},{"key":"ref_15","first-page":"407","article-title":"Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children\u2019s Oncology Group","volume":"130","author":"Cooper","year":"2017","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2007-04-084293","article-title":"Outcomes in CCG-2961, a children\u2019s oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: A report from the children\u2019s oncology group","volume":"111","author":"Lange","year":"2008","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2010.30.6829","article-title":"Response-Guided Induction Therapy in Pediatric Acute Myeloid Leukemia with Excellent Remission Rate","volume":"29","author":"Abrahamsson","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1200\/JCO.2014.58.3518","article-title":"Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia","volume":"33","author":"Chen","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.2012.43.7384","article-title":"Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group","volume":"31","author":"Kaspers","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Rasche, M., Zimmermann, M., Steidel, E., Alonzo, T., Aplenc, R., Bourquin, J.-P., Boztug, H., Cooper, T., Gamis, A., and Gerbing, R. (2021). Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. Cancers, 13.","DOI":"10.3390\/cancers13102336"},{"key":"ref_21","unstructured":"U.S. Department of Health and Human Services Food and Drug Administrations (2021, September 22). Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment; Guidance for Industry. August 2020, Available online: https:\/\/www.fda.gov\/media\/140821\/download."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.blre.2018.03.006","article-title":"Time to repeal and replace response criteria for acute myeloid leukemia?","volume":"32","author":"Bloomfield","year":"2018","journal-title":"Blood Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2012.229","article-title":"The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: Results from the LRF AML14 and NCRI AML16 pick-a-winner comparison","volume":"27","author":"Burnett","year":"2013","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/blood-2013-04-496596","article-title":"Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival","volume":"122","author":"Burnett","year":"2013","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1756-8722-6-29","article-title":"Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: A single centre retrospective study of 227 consecutive patients","volume":"6","author":"Scheepers","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ajh.24016","article-title":"Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients >\/=60 years old","volume":"90","author":"Gupta","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/616\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:08:08Z","timestamp":1760134088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14030616"],"URL":"https:\/\/doi.org\/10.3390\/cancers14030616","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]}}}